Invesaro

Stocks Health care PODD

NASDAQ · Health care

Insulet Corp (PODD)

Insulet Corp brought in $3.1B of revenue over the twelve months to June 30, 2026, up 29.4% from a year earlier. Net income was $375.3M, a net margin of 12.3%. Operating cash flow minus capital spending left $377.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $534.9M in cash against $18.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Price
$136.13
+0.26% on the day · September 25, 2026
52-week range $126.40 to $354.88
Market cap
$9.4B
Revenue (last 12 months)
$3.1B
+29.4% year on year
Net margin
12.3%
P/E
39.1
on FY2025 diluted EPS

What Insulet Corp does

Insulet Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PODD.

Revenue and profit by year

Revenue
FY18: $563.8M $563.8M FY18FY19: $738.2M $738.2M FY19FY20: $904.4M $904.4M FY20FY21: $1.1B $1.1B FY21FY22: $1.3B $1.3B FY22FY23: $1.7B $1.7B FY23FY24: $2.1B $2.1B FY24FY25: $2.7B $2.7B FY25
Net income
FY18: $3.3M $3.3M FY18FY19: $11.6M $11.6M FY19FY20: $6.8M $6.8M FY20FY21: $16.8M $16.8M FY21FY22: $4.6M $4.6M FY22FY23: $206.3M $206.3M FY23FY24: $418.3M $418.3M FY24FY25: $247.1M $247.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.7B$473.8M$247.1M$3.48$377.7M
2024$2.1B$308.9M$418.3M$5.78$305.3M
2023$1.7B$220.1M$206.3M$2.94$70.1M
2022$1.3B$37.6M$4.6M$0.07-$3.9M
2021$1.1B$126M$16.8M$0.24-$180M
2020$904.4M$51.5M$6.8M$0.10-$45M

Latest SEC filings

What Insulet Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 21, 2026
    Material agreement 8-K
  2. September 16, 2026
    Executive or director change 8-K
  3. September 10, 2026
    Executive or director change 8-K
  4. August 6, 2026
    Passive stake changed SCHEDULE 13G/A
  5. August 5, 2026
    Quarterly report 10-Q · period to June 30, 2026
  6. August 5, 2026
    Quarterly results 8-K
  7. June 25, 2026
    Executive or director change 8-K
  8. May 28, 2026
    Conflict minerals disclosure SD
  9. May 26, 2026
    Investor disclosure 8-K
  10. May 21, 2026
    Bylaws or fiscal year changed 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PODD

What does Insulet Corp do?

Insulet Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PODD.

Is Insulet Corp profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $375.3M on revenue of $3.1B, a net margin of 12.3%.

How much revenue does Insulet Corp make?

Over the twelve months to June 30, 2026 Insulet Corp reported revenue of $3.1B. That is 29.4% more than a year earlier.

When did Insulet Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 21, 2026.

Similar companies

MDLN
Medline Inc.
SYK
Stryker Corp
MMM
3M Co
BDX
Becton Dickinson & Co
BSX
Boston Scientific Corp
BAX
Baxter International Inc

Follow PODD

Get an email when Insulet Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow PODD: get an email when it files

Where the numbers come from

Financial figures are the values Insulet Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.